A novel series of non-nucleoside inhibitors of inosine 5'-monophosphate dehydrogenase with immunosuppressive activity

Biochemical Pharmacology

Volumn 58, Issue 5, 1999, Pages 867-876

  Franklin, Trevor J ^a   Morris, William P ^a   Jacobs, Vivien N ^a   Culbert, Eric J ^a   Heys, Christine A ^a   Ward, Walter H J ^a,b   Cook, Peter N ^a   Jung, Frédéric ^b   Plé, Patrick ^b  

^a ASTRAZENECA   (United Kingdom)

^b Centre de Recherches   (France)

Author keywords

GTP; Guanine nucleotides; Immunosuppression; IMP dehydrogenase; Mycophenolic acid; Pyridazines

Indexed keywords

ENZYME INHIBITOR; GUANOSINE TRIPHOSPHATE; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; PYRIDAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG POTENCY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL DIVISION; DRUG EVALUATION, PRECLINICAL; FEMALE; GUANOSINE TRIPHOSPHATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KINETICS; MICE; MICE, INBRED BALB C; PYRIDAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0032777686     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00170-7     Document Type: Article

References (19)

1. Weber G., Nakamura Y., Szekes T., Nagai M. Regulation of GTP synthesis. Adv Enzyme Regul. 32:1992;57-69.
2. Balzarini J., Karlsson A., Wang L., Bohman C., Horska K., Votruba I., Fridland A., Van Aerschot A., Herdewijn P., DeClerc E. Eicar (5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide. A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis. J Biol Chem. 268:1993;24591-24598.
3. Tricot C.J., Jarayam H.N., Lapis E., Natsumeda Y., Nichols C.R., Kneebone P., Heerema N., Weber G., Hoffman R. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5′-monophosphate dehydrogenase activity. Cancer Res. 49:1989;3696-3701.
4. Shaw L.M., Solinger H.W., Halloran P., Morris R.E., Yatscoff R.W., Ransom J., Tsina I., Keown P., Holt D.W., Lieberman R., Jaklitsch A., Potter J. Mycophenolate mofetil A report of the consensus panel . Ther Drug Monit. 17:1995;690-699.
5. Carr S.F., Papp E., Wu J.C., Natsumeda Y. Characteristics of human Type I and Type II IMP dehydrogenase. J Biol Chem. 268:1993;27286-27290.
6. Sintchak M.D., Fleming M.A., Futer O., Raybuck S.A., Chambers S.P., Caron P.R., Murcko M.A., Wilson K.P. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell. 85:1996;921-930.
7. Franklin T.J., Edwards G., Hedge P. Inosine 5′-monophosphate dehydrogenase as a chemotherapeutic target. Sahota A., Taylor M. Purine and Pyrimidine Metabolism in Man. Vol. VIII:1995;155-160 Plenum Press, New York.
8. Williams J.W., Morrison J.F. The kinetics of reversible tight-binding inhibition. Purich D.L. Methods in Enzymology. Vol. 63:1979;437-467 Academic Press, New York.
9. Mannervik B. Regression analysis, experimental error, and statistical criteria in the design and analysis of experiments for discrimination between rival kinetic models. Purich D.L. Methods in Enzymology. Vol. 87:1982;370-390 Academic Press, New York.
10. Franklin T.J., Jacobs V., Jones G., Plé P., Bruneau P. Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells. Cancer Res. 56:1996;984-987.
11. Franklin T.J., Morris W.P. Pharmacodynamics of the inhibition of GTP synthesis in vivo by mycophenolic acid. Adv Enzyme Regul. 34:1994;107-111.
12. Ward W.H.J., Cook P.N., Mirrlees D.J., Brittain D.R., Preston J., Carey F., Tuffin D.P., Howe R. (2,6-Dimethylphenylsulphonyl)nitromethane A new structural type of aldose reductase inhibitor which follows biphasic kinetics and uses an allosteric binding site . Biochem Pharmacol. 42:1991;2115-2123.
13. Yonetani T., Theorell H. Studies on liver alcohol dehydrogenase complexes. III. Multiple inhibition kinetics in the presence of two competitive inhibitors. Arch Biochem Biophys. 106:1964;243-251.
14. Franklin T.J., Cook J.M. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J. 113:1969;515-524.
15. Epinette W.W., Parker C.M., Jones E.L., Greist M.C. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol. 17:1987;962-971.
16. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol. 11:(Suppl 8):1993;S117-S119.
17. Lintrup J., Hyltoft-Petersen P., Knudtzon S., Nissen N.I. Metabolic studies in man with mycophenolic acid (NSC-129185), a new antitumor agent. Cancer Chemother Rep. 56:1972;229-235.
18. Allison A.C., Eugui E.M. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev. 136:1993;5-28.
19. Link J.O., Straub K. Trapping of an IMP dehydrogenase-substrate covalent intermediate by mycophenolic acid. J Am Chem Soc. 118:1996;2091-2092.